Jasper Therapeutics Inc. (JSPR)

Equities Analysts Offer Predictions for Jasper Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:JSPR)

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) – Equities research analysts at Capital One Financial upped their Q2 2024 earnings per share estimates for shares of Jasper Therapeutics in a research report issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of ($1.19) for the quarter, up from their prior estimate of ($1.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.35) per share. Capital One Financial also issued estimates for Jasper Therapeutics’ FY2024 earnings at ($4.64) EPS, FY2025 earnings at ($5.08) EPS, FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($2.74) EPS and FY2028 earnings at $2.23 EPS. A number of other equities research analysts also recently commented on JSPR. Oppenheimer reiterated an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Evercore ISI started coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 target price for the company. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 target price on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $64.29. Read Our Latest Stock Report on JSPR Jasper Therapeutics Price Performance JSPR stock opened at $23.02 on Monday. The firm has a market cap of $346.68 million, a PE ratio of -4.09 and a beta of 2.25. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a 50 day simple moving average of $25.12 and a 200 day simple moving average of $15.85. Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. Institutional Investors Weigh In On Jasper Therapeutics A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. grew its stake in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics in the 4th quarter worth about $197,000. Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $140,000. Finally, StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Hedge funds and other institutional investors own 79.85% of the company’s stock. Jasper Therapeutics Company Profile (Get Free Report) Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. Read More Five stocks we like better than Jasper Therapeutics What is the Euro STOXX 50 Index? MarketBeat Week in Review – 5/13 – 5/17 Low PE Growth Stocks: Unlocking Investment Opportunities Take-Two Interactive Software Offers 2nd Chance for Investors How to Effectively Use the MarketBeat Ratings Screener Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook